Senaste försöken


EudraCT Number: 2022-004078-53 Sponsor Protocol Number: 83403 Start Date: 2023-08-22
Sponsor Name: Academic Medical Center (AMC), department of Internal Medicine
Full Title: Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping
Medical condition: - Plaque characteristics - Systemic inflammation
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002788-30 Sponsor Protocol Number: IMVT-1401-3202 Start Date: 2023-07-13
Sponsor Name: Immunovant Sciences, GmbH
Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Medical condition: Thyroid Eye Disease (TED)
Disease: Version SOC Term Classification Code Term Level
23.1 100000004853 10084358 Thyroid eye disease LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) BE (Ongoing) LV (Ongoing) HU (Ongoing) SK (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003584-18 Sponsor Protocol Number: KKS-307 Start Date: 2023-06-26
Sponsor Name: Philipps University Marburg
Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
Disease: Version SOC Term Classification Code Term Level
21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022619 Interstitial pulmonary fibrosis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000430-42 Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT Start Date: 2023-06-22
Sponsor Name: Janssen-Cilag International NV
Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Medical condition: Major Depressive Disorder (MDD)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004873 10025453 Major depressive disorder NOS LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) BG (Ongoing) ES (Ongoing) PT (Ongoing) SK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000692-39 Sponsor Protocol Number: IVY Start Date: 2023-06-19
Sponsor Name: Amsterdam University Medical Center
Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva
Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
Population Age: Adults Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003594-33 Sponsor Protocol Number: EORTC-1984-BCG Start Date: 2023-06-16
Sponsor Name: European Organisation for Research and Treatment of Cancer (EORTC)
Full Title: Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer (NOBLE)
Medical condition: Triple negative breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000690-73 Sponsor Protocol Number: BAY86-5321/21912 Start Date: 2023-06-06
Sponsor Name: Bayer AG
Full Title: A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive customized Treatment Intervals in Patients ≥50 Years of Age wi...
Medical condition: Neovascular (wet) age-related macular degeneration
Disease: Version SOC Term Classification Code Term Level
20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Prematurely Ended) ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000054-28 Sponsor Protocol Number: OLIGOTREAT Start Date: 2023-06-02
Sponsor Name: Klinikum der Universität München
Full Title: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)
Medical condition: Schizophrenia
Disease: Version SOC Term Classification Code Term Level
20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002407-37 Sponsor Protocol Number: BET-PSMA-121 Start Date: 2023-05-22
Sponsor Name: Blue Earth Therapeutics Limited
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
Population Age: Adults, Elderly Gender: Male
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003398-51 Sponsor Protocol Number: R-Pola-Glo Start Date: 2023-05-16
Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in...
Medical condition: aggressive large B-cell lymphoma
Disease: Version SOC Term Classification Code Term Level
20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)